Skip to Content

Lexicon Pharmaceuticals Inc LXRX

Morningstar Rating
$2.40 +0.21 (9.59%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

LXRX is trading at a 54% discount.
Price
$2.14
Fair Value
$7.17
Uncertainty
Extreme
1-Star Price
$98.70
5-Star Price
$8.60
Economic Moat
Xmrj
Capital Allocation
Nmvtylgw
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LXRX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.19
Day Range
$2.132.47
52-Week Range
$0.923.79
Bid/Ask
$2.37 / $2.45
Market Cap
$590.97 Mil
Volume/Avg
7.1 Mil / 4.7 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
440.77
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
285

Comparables

Valuation

Metric
LXRX
TVTX
RETA
Price/Earnings (Normalized)
37.91
Price/Book Value
6.312.8974.73
Price/Sales
440.773.94283.91
Price/Cash Flow
Price/Earnings
LXRX
TVTX
RETA

Financial Strength

Metric
LXRX
TVTX
RETA
Quick Ratio
5.423.312.82
Current Ratio
5.603.473.21
Interest Coverage
−13.11−34.10−1.31
Quick Ratio
LXRX
TVTX
RETA

Profitability

Metric
LXRX
TVTX
RETA
Return on Assets (Normalized)
−68.99%−2.68%−51.74%
Return on Equity (Normalized)
−130.40%−12.41%
Return on Invested Capital (Normalized)
−74.77%−5.04%−186.99%
Return on Assets
LXRX
TVTX
RETA
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRNskhspgsbYswt$570.1 Bil
VRTX
Vertex Pharmaceuticals IncWtrkwhhJypkb$108.0 Bil
REGN
Regeneron Pharmaceuticals IncSvxhbvdwKrmkplt$105.6 Bil
MRNA
Moderna IncVhyrptflSrt$40.8 Bil
ARGX
argenx SE ADRNhfkvvybYjkf$23.5 Bil
BNTX
BioNTech SE ADRXxlblgznLhc$21.9 Bil
ALNY
Alnylam Pharmaceuticals IncJxwxddxzHkjgz$18.8 Bil
BMRN
Biomarin Pharmaceutical IncGmxlnddhNwrnw$16.5 Bil
RPRX
Royalty Pharma PLC Class AMncwmscrgnGcwkkhf$13.6 Bil
INCY
Incyte CorpHvhwqhghSpsmjd$12.8 Bil

Sponsor Center